Kathryn V. Papp, Sarah Tomaszewski Farias, Marjorie Howard, Amber Thro, Tiia Ngandu, Brad Caudle, Bonnie C. Sachs, Michelle Chan, Kristin R. Krueger, Elizabeth R. T. Hartman, Athene Lee, Michele K. York, Marie T. Austin, Kathryn E. Demos, Thomas M. Holland, Xiaoyan Leng, Rema Raman, Heather M. Snyder, Maria C. Carrillo, Rachel A. Whitmer, Mark A. Espeland, Laura D. Baker, the US POINTER Study Group
{"title":"Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER","authors":"Kathryn V. Papp, Sarah Tomaszewski Farias, Marjorie Howard, Amber Thro, Tiia Ngandu, Brad Caudle, Bonnie C. Sachs, Michelle Chan, Kristin R. Krueger, Elizabeth R. T. Hartman, Athene Lee, Michele K. York, Marie T. Austin, Kathryn E. Demos, Thomas M. Holland, Xiaoyan Leng, Rema Raman, Heather M. Snyder, Maria C. Carrillo, Rachel A. Whitmer, Mark A. Espeland, Laura D. Baker, the US POINTER Study Group","doi":"10.1002/alz.70216","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Validation of the primary cognitive composite and baseline cognitive characteristics are presented for the US-Study-to-Protect-Brain-Health-Through-Lifestyle-Intervention-to-Reduce-Risk (US POINTER).</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>US POINTER is a multicenter, randomized clinical trial of two lifestyle interventions testing cognitive benefit in older adults without significant cognitive impairment but at-risk for decline due to well-established factors. Cognition is measured using a global cognitive composite (US POINTER modified Neuropsychological Test Battery-PmNTB).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>The PmNTB is a valid cognitive composite, exhibiting good psychometric properties and tracking with other established outcomes. Among the 2111 enrolled participants (mean age = 68.2 years, 69% women, 31% from race and ethnic minoritized groups), demographic characteristics alone (age, sex, education, race, ethnicity) explained more variance in cognition measured using the PmNTB (25.94%) compared with cardiovascular and family history risk factors combined (added < 3% explained variance).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>In a large diverse older adult cohort, demographic features rather than well-established risks for cognitive decline correlate with baseline global cognition.</p>\n \n <p>Clinical trial registration number: NCT03688126</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Demographic characteristics explain baseline cognition in at-risk older adults.</li>\n \n <li>The POINTER Modified Neuropsychological Test Battery (PmNTB) is a valid measure.</li>\n \n <li>Worse cognition tracks with E4+, high HbA1c, current smoking, Framingham heart risk.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 7","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70216","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70216","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Validation of the primary cognitive composite and baseline cognitive characteristics are presented for the US-Study-to-Protect-Brain-Health-Through-Lifestyle-Intervention-to-Reduce-Risk (US POINTER).
METHODS
US POINTER is a multicenter, randomized clinical trial of two lifestyle interventions testing cognitive benefit in older adults without significant cognitive impairment but at-risk for decline due to well-established factors. Cognition is measured using a global cognitive composite (US POINTER modified Neuropsychological Test Battery-PmNTB).
RESULTS
The PmNTB is a valid cognitive composite, exhibiting good psychometric properties and tracking with other established outcomes. Among the 2111 enrolled participants (mean age = 68.2 years, 69% women, 31% from race and ethnic minoritized groups), demographic characteristics alone (age, sex, education, race, ethnicity) explained more variance in cognition measured using the PmNTB (25.94%) compared with cardiovascular and family history risk factors combined (added < 3% explained variance).
DISCUSSION
In a large diverse older adult cohort, demographic features rather than well-established risks for cognitive decline correlate with baseline global cognition.
Clinical trial registration number: NCT03688126
Highlights
Demographic characteristics explain baseline cognition in at-risk older adults.
The POINTER Modified Neuropsychological Test Battery (PmNTB) is a valid measure.
Worse cognition tracks with E4+, high HbA1c, current smoking, Framingham heart risk.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
